Cargando…
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Evasion from apoptosis is an important hallmark of cancer cells. Alterations of apoptosis pathways are especially critical as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics. Thus, successful induction of apoptosis using no...
Autores principales: | Lim, Bora, Greer, Yoshimi, Lipkowitz, Stanley, Takebe, Naoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721450/ https://www.ncbi.nlm.nih.gov/pubmed/31370269 http://dx.doi.org/10.3390/cancers11081087 |
Ejemplares similares
-
TIC10/ONC201: a bend in the road to clinical development
por: Greer, Yoshimi Endo, et al.
Publicado: (2015) -
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
por: Kundu, Manjari, et al.
Publicado: (2022) -
A new tool in the arsenal
por: Venturini, Andrea, et al.
Publicado: (2021) -
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
por: Greer, Yoshimi Endo, et al.
Publicado: (2019) -
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer
por: Wedam, Rohan, et al.
Publicado: (2023)